Current usage of Pembrolizumab in triple negative breast cancer (TNBC)

Expert Rev Anticancer Ther. 2024 Apr 9. doi: 10.1080/14737140.2024.2341729. Online ahead of print.ABSTRACTINTRODUCTION: The use of immune checkpoint inhibitors (ICI) targeting the PD-1/PD-L1 pathway has changed the landscape in the treatment of triple negative breast cancer (TNBC). The ICI pembrolizumab in combination with chemotherapy now forms a standard of care for the treatment of advanced PD-L1 positive TNBC and as part of neoadjuvant therapy for high-risk early-stage disease. Evidence in this space is rapidly advancing.AREAS COVERED: This review aims to highlight the evolving role of immunotherapy in TNBC management and to discuss current challenges. The studies in this review were searched from PubMed and ClinicalTrials.gov.EXPERT OPINION: The KEYNOTE-522 trial demonstrated that the addition of peri-operative pembrolizumab to neoadjuvant chemotherapy improves patient outcomes in early-stage TNBC. However, critical questions remain including how to select which patients truly gain benefit from the addition of pembrolizumab; the optimal duration of therapy, and the optimal adjuvant therapy depending on pathologic response.PMID:38594892 | DOI:10.1080/14737140.2024.2341729
Source: Expert Review of Anticancer Therapy - Category: Cancer & Oncology Authors: Source Type: research